TLDR

• Article frames model risk management (MRM) as the primary governance layer for adaptive AI in life sciences, sitting alongside GxP and QMS to control models used in discovery, clinical, manufacturing and regulatory workflows.

• It argues that legacy “validate once and freeze” approaches cannot manage models that retrain and drift, and that this gap is already slowing or blocking deployment of AI in regulated use cases.

• MRM introduces continuous monitoring, explainability, retraining governance and linkage of technical model changes to business and compliance risk, using specialised platforms rather than manual controls.

• Organisations are advised to embed MRM from the start of AI projects, integrate it with existing quality systems, invest in monitoring and documentation infrastructure, and engage early with evolving FDA and EMA guidance on AI for regulatory decision‑making.

The pharmaceutical industry built its entire compliance playbook on something that no longer exists [1]. We validated systems once, documented them meticulously, and assumed they would stay predictable forever [2, 10]. That was the deal with GMP and GLP. The core pillars of GxP in life sciences compliance, alongside GCP for clinical activities, all designed around well-controlled, static systems [1, 3, 4].

Then AI showed up and flipped the table.

Today’s machine learning models don’t sit still. They drift, retrain, and adjust their parameters based on new data, meaning their behavior can change materially even if the surrounding infrastructure is untouched [6, 12]. For those managing regulatory compliance and digital transformation, Model Risk Management (MRM) isn’t just another framework; it’s the only bridge between the innovation boards want and the compliance auditors need [8, 9, 15].

The GxP Assumption That’s Breaking Down

Traditional validation relies on locking down requirements and freezing the system in a validated “box” [2, 10]. Adaptive AI doesn’t work like that.

Imagine a predictive model for clinical trial recruitment. Three months in, patient demographics shift, the underlying data distribution changes, and the model retrains automatically to stay accurate [5, 12]. Mathematically, it is now a different model [6]. However, legacy CSV and GAMP frameworks have almost no prescriptive language for this kind of continuous evolution [2, 10]. This disconnect is currently blocking legitimate AI applications across drug discovery, manufacturing, and clinical operations [5, 11].

The Squeeze: Board Pressure vs. Auditor Trust

There’s real pressure to move fast. Competitors are adopting AI for molecular simulations and manufacturing optimisation [11]. C-suites are asking why you aren’t, while vendors promise faster time-to-market and lower costs [11, 12].

But the regulatory reality is clear: FDA and EMA communications indicate that AI models carry the same compliance weight as legacy systems regarding quality, data integrity, and patient safety [13, 14, 17]. Traditional risk frameworks catch software configuration issues but often fail to detect model drift or training data bias that emerges only after deployment [5, 7, 18]. This is where adoption stalls [12].

Model Risk Management Changes the Game

MRM matured in financial services, governing models for algorithmic trading and fraud detection that were too important to fail but too dynamic to “validate once and forget” [6, 7].

MRM flips the compliance model in several ways:

• Continuous Monitoring: Moves from one-time validation to real-time performance tracking and automatic revalidation triggers [8, 15].

• Transparency: Insists on explainability, ensuring teams understand why a model makes a specific decision [5, 8, 16].

• Evolutionary Governance: Tracks retraining events and data quality shifts without freezing innovation [9, 10, 15].

• Connected Risk: Links technical model shifts to actual business and compliance risk [6, 9, 15].

The Tools That Make This Real

Implementation requires a new generation of AI governance platforms [8]. You need:

1. Real-time Monitoring Dashboards: To expose performance and data drift against baselines [8, 15].

2. Automated Documentation: To capture validation evidence and metadata in regulator-recognised formats [8].

3. Data Quality Frameworks: Since data is the primary control surface in adaptive AI [5, 12, 17].

4. Explainability Features: To satisfy internal governance and regulatory scrutiny [5, 16].

5. Governance Workflows: To formalise revalidation and retraining approvals [9, 15, 17].

Making This Happen: Your Next Steps

Leading organisations aren’t treating MRM as a late-stage checkbox; they are baking it into their strategy from day one [5, 11]. This means:

• Early Partnership: Data science, IT, and quality must collaborate on instrumentation and controls before shipping [12, 17].

• Breaking Silos: Integrating model risk into existing Quality Management Systems (QMS) [10, 15].

• Investing in Infrastructure: Moving beyond manual spreadsheets to platforms capable of scale [8, 15].

• Regulatory Engagement: FDA and EMA are actively refining guidance, such as the 2025 draft on AI for regulatory decision-making [13, 17, 18]. Early pilots can help shape these expectations.

The Bottom Line

Big Pharma didn’t choose to rethink GxP; adaptive AI forced the conversation. MRM is becoming the primary way to operationalise data integrity and risk-based oversight for systems that learn [1, 15]. Mastering this bridge is what will define the next era of life sciences.

Advancing with model risk management? Discover our curated list to see how industry leaders are accelerating timelines, implementing AI solutions in healthcare and gaining a competitive edge. Follow us for more actionable AI insights shaping the future of life sciences and AI in healthcare.

References

1. AVS Life Sciences. “GxP Meaning: Defining Good Practices in Life Sciences.” Aug 2025.

2. Eupry. “What are the GxPs in pharma | The key components.” Jan 2025.

3. QSGROUP. “Understanding compliance across GMP, GLP, GCP, and GDP.” Sep 2025.

4. Skillpad. “Overview of GxP | GLP, GCP & GMP Compliance Training.” Oct 2025.

5. Intuition Labs. “Factors Hindering AI Adoption in Life Sciences: 2023–2025.” Jan 2025.

6. Weights & Biases. “What is model risk management in finance?” Jul 2024.

7. OCC. “Model Risk Management | Comptroller’s Handbook (SR 11-7 context).” Aug 2022.

8. ValidMind. “Ongoing Monitoring of Models for Regulatory Compliance and Robust Risk Management.” Apr 2025.

9. Evalueserve. “Model Risk Governance.” May 2023.

10. Dickson Data. “Understanding Pharma GxP: A Guide to Good Practices.” Feb 2025.

11. Biopharm International. “Achieving Real Impact: Navigating the Data and Regulatory Barriers to AI Adoption in Biopharma.” Jan 2025.

12. Pharmaceutical Technology. “Thomas, F. Barriers to AI Adoption. Pharmaceutical Technology Europe 2024 36 (9).

13. FDA. “Artificial Intelligence for Drug Development.” Dec 2025.

14. EMA. “Artificial Intelligence | European Medicines Agency.” Nov 2025.

15. Grant Thornton. “Facilitating Ongoing Monitoring in Model Risk Management.” Jun 2023.

16. Moody’s. “Model Risk and Governance Resources.” Mar 2025.

17. FDA. “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products.” Jan 2025 draft guidance.

18. Atlas Compliance. “What’s new in the FDA’s 2025 AI/ML draft guidance?” Nov 2025.